HER-2 peptide-based vaccine: Potential to prevent breast cancer recurrence?

Researchers at the University of Texas MD Anderson Cancer Center, Brooke Army Medical Center, Uniformed Services University of the Health Sciences, and the Saint Savas Cancer Hospital, Cancer Immunology and Immunotherapy Center in Athens, Greece, have uncovered a new vaccine that indicates possible prevention of breast cancer recurrence. The vaccine in question, HER2 (human epidermal growth factor receptor 2), has been shown to "elicit a powerful immune response...the ability to improve recurrence rates...and is well tolerated in an adjuvant setting." The findings of this study will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 in Chicago. To read more about this vaccine, click here.